APOA1 and stroke disorder: The AEGIS-II trial found that among 18 219 patients with AMI, multivessel CAD, and additional CV risk factors, four weekly infusions of CSL112 (a human plasma-derived apolipoprotein A1 formulated with phosphatidylcholine) did not reduce the risk of recurrent CV events (MI, stroke, or CV death) at 90 days as compared with placebo (4.8% vs.